Anticoagulatory Role of an Ergot Mesylate: Hydergine

Thrombosis can be life threatening, necessitating therefore its instant treatment. Hydergine, a nootropic agent is used as a cognition enhancer in stroke patients but relatively little is known about its anti-thrombolytic effect. To investigate this aspect, in vivo and ex vivo experiments were designed and conducted. Three groups of rats were injected 1.5mg, 3.0mg and 4.5mg hydergine intraperitonealy with and without prior exposure to fresh plasma. Positive and negative controls were run in parallel. Animals were sacrificed after 1.5hrs and BT, CT, PT, INR, APTT, plasma calcium levels were estimated. For ex vivo analyses, each 1ml blood aspirated was exposed to 0.1mg, 0.2mg, 0.3mg dose of hydergine with parallel controls. Parameters analyzed were as above. Statistical analysis was through one-way ANOVA. Dunken’s and Tukey’s tests provided intra-group variance. BT, CT, PT, INR and APTT increased while calcium levels dropped significantly (P<0.05). Ex vivo, CT, PT and APTT were elevated while plasma calcium levels lowered significantly (P<0.05). Our study suggests that hydergine may act as a thrombolytic agent but warrants further studies to elucidate this role of ergot mesylates. Keywords—Hydergine; Coagulation assays; plasma calcium; ergot mesylates; thrombosis